UNSPSC 51172120: Ciclactate

This classification denotes an antispasmotic agent with the molecular formula C12H22O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MYS6082G8G, chemically known as 3,3,5-trimethylcyclohexyl lactate. but generally known as ciclactate, which bears US NIH Compound Identifier 193969. European Medicines Agency schedules Ciclactate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06233MIG.

UNSPSC 51172120 Ciclactate, a Commodity code, addresses drug-testing and specimen-collection services for criminal-justice populations, though the code designation appears misaligned with the actual work state and local governments are soliciting under it. State and local corrections and community-supervision agencies procure immunoassay screening with confirmatory testing (LC/MS/MS or GC/MS), specimen collection and handling at fixed sites, Interactive Voice Response systems for randomized testing notifications, and alternative testing methodologies including oral fluid and hair analysis. Vendors must maintain laboratory certification from SAMHSA, Texas DPS, or CAP and price services on a per-test basis across three models: screening only, confirmation after screening, and screening with automatic confirmation of positives. All costs including staffing, freight, delivery, and insurance are bundled into per-test pricing with no separate surcharges permitted. Issuing bodies include county community-supervision departments operating criminal-justice systems under state appropriations.

Collin County Community Supervision and Corrections Department issued RFP 2026-327 for Offender Specimen Collection and Drug Testing Services on September 25, 2026, with a response deadline of July 23, 2026 at 2:00 p.m., requesting proposals to staff collection sites in Plano and McKinney during weekday business hours and five Saturdays annually. The contract encompasses approximately 25,031 annual tests across five- and six-panel screens with ancillary testing, carries an estimated value of $600,000, and runs two years commencing September 1, 2026, with three optional one-year renewals not to exceed five years total. Evaluation weights vendor understanding and qualifications (55 points combined), client references (15 points), and cost (30 points), with optional Phase 2 demonstrations and interviews available for up to 30 additional points. Price redetermination is limited to September 1 anniversaries based on medical Consumer Price Index increases not exceeding 3.0 percent annually. The anticipated award date is August 10, 2026. Funding derives from Texas Department of Criminal Justice-Community Justice Assistance Division appropriations, subject to annual availability.